Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $14.2750.

A number of brokerages recently weighed in on NAGE. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Canaccord Genuity Group reduced their price objective on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of NAGE. Vanguard Group Inc. purchased a new stake in shares of Niagen Bioscience during the third quarter valued at approximately $37,522,000. Arrowstreet Capital Limited Partnership purchased a new stake in Niagen Bioscience during the 3rd quarter worth $13,405,000. UBS Group AG acquired a new position in Niagen Bioscience in the 3rd quarter worth $11,160,000. Qube Research & Technologies Ltd acquired a new stake in shares of Niagen Bioscience during the third quarter valued at about $8,175,000. Finally, Millennium Management LLC purchased a new stake in shares of Niagen Bioscience during the third quarter worth about $7,224,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Niagen Bioscience Stock Up 3.1%

Shares of NAGE stock opened at $5.01 on Tuesday. Niagen Bioscience has a fifty-two week low of $4.74 and a fifty-two week high of $14.69. The firm’s 50 day moving average price is $6.00 and its two-hundred day moving average price is $7.41. The stock has a market cap of $399.85 million, a price-to-earnings ratio of 20.88 and a beta of 2.35.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.